ondasdechoque.org
PT-BR

How shockwaves might act in knee osteoarthritis: a 2026 review of cell, animal and clinical studies · Lab study · 2026

How might shockwave act on cartilage and bone in knee arthritis?

This review collects 12 animal experiments, mostly in rats, and 12 studies in people. In the animals, treatment was followed by less cartilage breakdown, fewer dying cartilage cells and better bone beneath. Studies in people mainly measured pain and function; they have not shown human cartilage protected or rebuilt.

Explores how shockwave works
animal experiments, 11 of them in rats
12
studies in people with knee arthritis, 18 to 186 people each
12
year published
2026

Good to know: 8 of the 12 animal experiments came from one research group.

Chen Y, Song S, Zhu Y, et al. International Journal of Molecular Medicine, 2026 · Read the paper ↗

The treatment

Animal exposures (Table I)
Rats: 0.068–0.25 mJ/mm² with 500–800 impulses, with the number of sessions not stated for most rows; one dose-finding study gave 0.096, 0.128 or 0.16 mJ/mm² at 4 Hz, 800 impulses, weekly for 4 weeks. Rabbits: 600 impulses at 1.5×10⁵ Pa, three times within 1 week.
Clinical regimens (Table II)
Focused settings of 0.04–0.4 mJ/mm² or radial settings of 2.0–3.0 bar; 800–4,000 impulses per session where stated; schedules from three sessions in total to four sessions a week for 4 weeks (one row gives five sessions at 3-day intervals "for a total of 12 weeks"). Two studies did not state impulse numbers.
Focused versus radial devices
The review describes focused waves as concentrating energy at depth (for example the bone–cartilage interface) and radial waves as dispersing energy in superficial tissue, and says direct comparisons are limited.

Who took part

Rats and rabbits with knee arthritis caused by surgery or chemicals, cells grown in the lab, and people with knee arthritis in 12 clinical studies.

Side effects

One trial reported some negative effects on cartilage; the authors note that too much energy may worsen arthritis.

All the numbers and the full appraisal
FROM THE FULL PAPER

What the full paper reports.

No new participants. Table I lists 12 animal experiments: 11 in Sprague-Dawley rats, mostly with surgically induced (ligament transection, with or without meniscectomy) or chemically induced (MIA) knee osteoarthritis, and 1 in New Zealand white rabbits; the text gives 6–12 animals per group. Table II lists 12 clinical studies of knee osteoarthritis with 18 to 186 patients each. The mechanism sections draw on chondrocyte, osteoblast, macrophage and other cell studies, some from tissues other than the knee.

Proposed cell-signalling pathways1 reported outcome
01
As reported in the source

Proposed cell-signalling pathways

Proposed cell-signalling pathways Narrative finding

The review groups the proposed effects into four sets: anti-inflammatory (NF-κB suppression through PI3K, TLR4/MyD88 and NLRP3; regulation of nitric oxide; a shift of macrophages from the M1 to the M2 type), anti-apoptotic (DKK-1 inhibition, more Bcl-2, less cytochrome c and caspase-3), pro-proliferative (cyclin A2/CDK1, ATP release through pannexin-1 channels with ERK activation, PCNA/STAT3, PI3K/AKT/mTOR) and cartilage-matrix balance (MMPs, TIMPs, PI3K/AKT). Much of this rests on cell studies, some in non-knee cells, and on general osteoarthritis biology linked to shockwaves by inference. The authors state that whether shockwaves act directly on individual signalling molecules, and how the pathways relate, remains unanswered, and that a direct link to TIMP-1 is not established.

Analysis details and source

Qualitative finding; no effect estimate. The review says shockwaves increase IL-10 in chondrocytes and osteoblasts, but the title of one of the two cited studies reports down-regulation of IL-10 and TNF-α in osteoarthritic chondrocytes; the primary studies were not read.

Animal experiments (Table I)1 reported outcome
02
As reported in the source

Animal experiments (Table I)

Animal experiments (Table I) Narrative finding

Twelve experiments, 11 in rats and 1 in rabbits, assessed animals from 24 hours to 24 weeks after treatment. Reported changes include lower nitric oxide and caspase-3 in rabbits and, in rats, higher VEGF, BMP-2, type II collagen and PCNA, lower MMP-13, MMP-3 and DKK-1, and higher subchondral bone volume. One rat dose-finding study compared 0.096, 0.128 and 0.16 mJ/mm² and judged 0.096 mJ/mm² optimal in that experiment. The authors note small groups (6–12 animals), varied protocols, and observation of 4–12 weeks in some studies and up to 24 weeks in others.

Analysis details and source

Qualitative summary of Table I; animal results, not human treatment effects. Eight of the 12 rows come from one Taiwanese research group (Wang, Chou, Cheng and colleagues). One row (Kim 2019) is a study of rat chondrocytes and temporomandibular-joint osteoarthritis, not a knee model. The authors write that no major contradictory findings were observed, without describing how negative studies were sought.

Clinical studies (Table II)1 reported outcome
03
As reported in the source

Clinical studies (Table II)

Clinical studies (Table II) Narrative finding

Twelve clinical studies of 18–186 patients each mostly reported lower VAS and WOMAC scores after treatment. Against placebo, one trial in 105 women found a significant difference only in WOMAC pain on the treated side (P=0.038) and none in VAS (P=0.132); another found low-dose treatment better than placebo in mild-to-moderate disease but noted some negative effects on joint cartilage. A trial of focused versus radial devices favoured focused treatment (VAS P=0.01; WOMAC P<0.001; 6-minute walk P=0.003), whereas a meta-regression cited in the text favoured radial treatment for WOMAC function. Several studies compared energy levels; most follow-up was 6 months or less. The authors list lack of blinding, small samples and inconsistent CONSORT reporting.

Analysis details and source

P values are as quoted in Table II from the primary trials; the review reports no effect sizes, and the trials were not re-read here.

Structural versus symptomatic effects1 reported outcome
04
As reported in the source

Structural versus symptomatic effects

Structural versus symptomatic effects Narrative finding

The authors separate animal structural findings from human symptom relief: high-quality human trials with serial arthroscopy or quantitative MRI are scarce, clinical proof that shockwaves produce measurable cartilage regeneration or joint-space preservation is insufficient, and animal structural effects should not be directly extrapolated to patients. The abstract nonetheless says accumulating evidence indicates that shockwaves can slow knee osteoarthritis progression; that statement rests on animal data.

Analysis details and source

Qualitative finding, including an abstract-versus-body difference in emphasis; no effect estimate.

Energy level and safety1 reported outcome
05
As reported in the source

Energy level and safety

Energy level and safety Narrative finding

The review cites a usual clinical range of 0.001–0.5 mJ/mm², a rat study in which energy above 0.5 mJ/mm² caused cartilage deterioration, and a guideline (International Society for Medical Shockwave Treatment) recommending 2,000–4,000 focused pulses at 0.25–0.6 mJ/mm² for knee osteoarthritis. A tendinopathy trial found no marked difference between 0.78 and 0.33 mJ/mm². An in vitro study in alginate cultures found no toxicity to chondrocytes. The authors say improper dosing may worsen osteoarthritis or reduce efficacy, and that the optimal energy is unresolved.

Analysis details and source

Extractor note: the upper end of the quoted guideline range (0.6 mJ/mm²) is above the 0.5 mJ/mm² level linked to cartilage damage in rats; the review does not discuss this.

How treatment was delivered
Animal exposures (Table I)

Rats: 0.068–0.25 mJ/mm² with 500–800 impulses, with the number of sessions not stated for most rows; one dose-finding study gave 0.096, 0.128 or 0.16 mJ/mm² at 4 Hz, 800 impulses, weekly for 4 weeks. Rabbits: 600 impulses at 1.5×10⁵ Pa, three times within 1 week.

Clinical regimens (Table II)

Focused settings of 0.04–0.4 mJ/mm² or radial settings of 2.0–3.0 bar; 800–4,000 impulses per session where stated; schedules from three sessions in total to four sessions a week for 4 weeks (one row gives five sessions at 3-day intervals "for a total of 12 weeks"). Two studies did not state impulse numbers.

Focused versus radial devices

The review describes focused waves as concentrating energy at depth (for example the bone–cartilage interface) and radial waves as dispersing energy in superficial tissue, and says direct comparisons are limited.

HARMS & TOLERABILITY

The review has no harms data of its own. It describes clinical safety as favourable, but it also states that only two of the systematic reviews it cites addressed side effects at all, both without comprehensive, standardised safety criteria. It further notes that excessive energy may worsen osteoarthritis and that one trial reported some negative effects on joint cartilage. Funding came from the Sichuan Provincial Administration of Traditional Chinese Medicine and the Sports Medicine Key Laboratory of Sichuan Province; the authors declare no competing interests, and no device-maker ties are reported.

LIMITS OF THE ANALYSIS

Author-reported: animal studies had small groups (6–12 animals), varied observation periods and heterogeneous energy protocols; human trials often lacked blinding, had modest samples and inconsistent CONSORT adherence; durability beyond 6 months is understudied.

Extractor assessment: despite a PRISMA-style search, there is no risk-of-bias appraisal or pooling, inclusion was English-only, and how the 24 tabulated studies were chosen from 85 included is not explained.

Extractor assessment: the clinical section repeats efficacy statements from other reviews (proven safe and effective, superior to physical therapy and placebo) without appraising them, and attributes a moderate rating to the GRADE system itself rather than to a specific review's certainty assessment.

Extractor assessment: eight of the 12 animal experiments come from one research group, limiting independent replication; Table I includes a temporomandibular-joint study and defines ACLT as ligament "transfer"; the IL-10 statement differs from a cited study's title.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: animal studies had small groups (6–12 animals), varied observation periods and heterogeneous energy protocols; human trials often lacked blinding, had modest samples and inconsistent CONSORT adherence; durability beyond 6 months is understudied.
  • Extractor assessment: despite a PRISMA-style search, there is no risk-of-bias appraisal or pooling, inclusion was English-only, and how the 24 tabulated studies were chosen from 85 included is not explained.
  • Extractor assessment: the clinical section repeats efficacy statements from other reviews (proven safe and effective, superior to physical therapy and placebo) without appraising them, and attributes a moderate rating to the GRADE system itself rather than to a specific review's certainty assessment.
  • Extractor assessment: eight of the 12 animal experiments come from one research group, limiting independent replication; Table I includes a temporomandibular-joint study and defines ACLT as ligament "transfer"; the IL-10 statement differs from a cited study's title.
Research review

Source-linked critical reading

Narrative review with a stated structured search (PubMed, EMBASE, Web of Science and Cochrane Library to July 2026; 85 studies included) covering cell-signalling, animal and clinical studies of shockwaves in knee osteoarthritis. It has a PRISMA-style flow chart but no risk-of-bias appraisal and no pooled estimate, and it included English-language articles only.

Reading depthMaterial consulted
Technical source record

Complete local PDF read (20 pages), including all sections, Tables I–II, Figures 1–5 and captions, funding, competing interests and references. The cited primary studies were not read.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Narrative review with a stated structured search (PubMed, EMBASE, Web of Science and Cochrane Library to July 2026; 85 studies included) covering cell-signalling, animal and clinical studies of shockwaves in knee osteoarthritis. It has a PRISMA-style flow chart but no risk-of-bias appraisal and no pooled estimate, and it included English-language articles only.

Participants and setting

No new participants. Table I lists 12 animal experiments: 11 in Sprague-Dawley rats, mostly with surgically induced (ligament transection, with or without meniscectomy) or chemically induced (MIA) knee osteoarthritis, and 1 in New Zealand white rabbits; the text gives 6–12 animals per group. Table II lists 12 clinical studies of knee osteoarthritis with 18 to 186 patients each. The mechanism sections draw on chondrocyte, osteoblast, macrophage and other cell studies, some from tissues other than the knee.

Treatment protocol

Animal exposures in Table I were 0.068–0.25 mJ/mm² with 500–800 impulses in rats, and 600 impulses at 1.5×10⁵ Pa three times in one week in rabbits. Clinical studies in Table II used focused settings of 0.04–0.4 mJ/mm² or radial settings of 2.0–3.0 bar, 800–4,000 impulses per session where stated, and schedules from three sessions in total to four sessions a week for 4 weeks; one row gives five sessions at 3-day intervals "for a total of 12 weeks". The review cites a guideline recommending 2,000–4,000 focused pulses at 0.25–0.6 mJ/mm² and a rat study in which energy above 0.5 mJ/mm² damaged cartilage. No single regimen is established.

Comparison

Animal studies compare treated with untreated osteoarthritic joints. Clinical studies in Table II used placebo, NSAIDs, hyaluronic acid, laser, kinesiotherapy, different energy levels, or focused versus radial devices; designs include randomised trials, one retrospective study and an 18-patient pilot. The review reports P values for some studies but no effect sizes.

What was measured

In cells and animals: inflammatory, apoptotic and proliferative signalling molecules, cartilage matrix enzymes (MMPs, TIMPs), cartilage histology, growth factors (VEGF, BMP-2, TGF-β1) and subchondral bone on micro-CT. In people: VAS, WOMAC, Lequesne index, KOOS, Roles and Maudsley score, range of motion, walking and stair tests, bone mineral density and joint effusion. No structural cartilage endpoint in people is reported.

Results and interpretation

In rats and in one rabbit study, treatment was followed by less cartilage breakdown, fewer dying cartilage cells, higher growth-factor markers (VEGF, BMP-2, TGF-β1) and a cell-proliferation marker (PCNA) and better subchondral bone measures. The proposed pathways (NF-κB, TLR4/MyD88, NLRP3, PI3K/AKT, DKK-1, YAP and others) come mainly from cell and animal work, and the authors say direct links and their order remain unclear. For people, the authors conclude that current evidence mainly supports short-term relief of pain and function; trials showing cartilage repair or preserved joint space are scarce, and animal structural effects should not be applied directly to patients. Against placebo, one trial in 105 women found a significant difference only in WOMAC pain on the treated side (P=0.038), not in VAS (P=0.132), and another noted some negative effects on cartilage.

Harms and disclosures

The review has no harms data of its own. It describes clinical safety as favourable, but it also states that only two of the systematic reviews it cites addressed side effects at all, both without comprehensive, standardised safety criteria. It further notes that excessive energy may worsen osteoarthritis and that one trial reported some negative effects on joint cartilage. Funding came from the Sichuan Provincial Administration of Traditional Chinese Medicine and the Sports Medicine Key Laboratory of Sichuan Province; the authors declare no competing interests, and no device-maker ties are reported.

Limitations

No risk-of-bias appraisal or pooling; English-only inclusion; mechanisms inferred largely from cell work and general osteoarthritis biology; eight of 12 animal experiments from one group; efficacy claims from other reviews repeated without appraisal; an abstract that states more than the body supports; a temporomandibular-joint study in the knee animal table. The authors themselves note small animal groups, heterogeneous protocols, unblinded and small human trials, and little follow-up beyond 6 months.

Applicability

Explanatory background on how shockwaves might act in an osteoarthritic knee and a map of the literature. It cannot estimate the size of benefit in people, show that human cartilage is protected or rebuilt, or recommend energy settings or a schedule.

What stronger evidence needs

Blinded, adequately sized randomised trials with standardised energy settings, follow-up beyond 6 months, structured harms reporting and structural endpoints (quantitative MRI or arthroscopy), plus independent replication of the animal findings outside a single research group.

THE ORIGINAL SOURCE

Read the original article.

Deciphering the function and mechanism of extracorporeal shock wave therapy in knee osteoarthritis (Review).

Chen Y, Song S, Zhu Y, Wang S, Hu J, Liu C, Cai Y, Hu Y. · International journal of molecular medicine · 2026

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →